摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-5-硝基甲苯 | 52488-28-5

中文名称
3-溴-5-硝基甲苯
中文别名
——
英文名称
1-bromo-3-methyl-5-nitrobenzene
英文别名
3-bromo-5-nitrotoluene;3-bromo-5-methylnitrobenzene
3-溴-5-硝基甲苯化学式
CAS
52488-28-5
化学式
C7H6BrNO2
mdl
MFCD06659815
分子量
216.034
InChiKey
MWFDNXJPZUOTJB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    68-72
  • 沸点:
    269.5℃
  • 密度:
    1.615±0.06 g/cm3 (20 ºC 760 Torr)
  • 闪点:
    120.0±21.8℃

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    45.8
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2904909090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:2c730db5b212ebfbd58e8811d46f113d
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Bromo-5-nitrotoluene
Synonyms: 3-Bromo-5-methylnitrobenzene

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-5-nitrotoluene
CAS number: 52488-28-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6BrNO2
Molecular weight: 216.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-溴-5-硝基甲苯potassium permanganate氢溴酸magnesium 作用下, 以 四氢呋喃甲醇甲苯 为溶剂, 反应 41.0h, 生成 大黄酸
    参考文献:
    名称:
    一种大黄酸的全合成工艺
    摘要:
    本发明涉及一种大黄酸的全合成工艺,以甲氧基邻苯二甲酸酐和格氏反应液为原料经缩合、脱水环合、甲氧基化、氧化、脱甲基反应后制备得大黄酸。
    公开号:
    CN106966891A
  • 作为产物:
    描述:
    4-硝基-2-甲苯胺 作用下, 生成 3-溴-5-硝基甲苯
    参考文献:
    名称:
    Nevile; Winther, Chemische Berichte, 1880, vol. 13, p. 963
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • <i>meta</i> ‐Nitration of Arenes Bearing <i>ortho</i> / <i>para</i> Directing Group(s) Using C−H Borylation
    作者:Xuejing Li、Xingwang Deng、Anthony G. Coyne、Rajavel Srinivasan
    DOI:10.1002/chem.201901633
    日期:2019.6.18
    of arenes bearing ortho/para directing group(s) using the iridium‐catalyzed C−H borylation reaction followed by a newly developed copper(II)‐catalyzed transformation of the crude aryl pinacol boronate esters into the corresponding nitroarenes in a one‐pot fashion. This protocol allows the synthesis of meta‐nitrated arenes that are tedious to prepare or require multistep synthesis using the existing
    在本文中,我们报道了荟萃芳烃的-nitration轴承邻/对位用铱催化的C-H硼化反应之后是新开发的铜(II)粗频哪醇的芳基硼酸酯入的催化的变换引导组(多个)以一锅的方式对应的硝基芳烃。该协议允许的合成元-nitrated芳烃是乏味来制备或使用现有的方法需要多步合成。该反应可耐受多种邻位/对位导向基团,例如-F,-Cl,-Br,-CH 3,-Et,-i Pr -OCH 3和-OCF 3。它还提供对π电子缺陷杂环的硝基衍生物(例如吡啶和喹啉衍生物)的区域选择性访问。该方法的应用在复杂分子的后期修饰中以及在以克级制备到FDA批准的药物Nilotinib途中的中间体中得到了证明。最后,我们证明了通过该策略获得的硝基产物也可以通过Baran的胺化方案直接转化为苯胺或受阻胺。
  • [EN] HETEROCYCLIC INHIBITORS OF PCSK9<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE PCSK9
    申请人:CARDIO THERAPEUTICS PTY LTD
    公开号:WO2018165718A1
    公开(公告)日:2018-09-20
    This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): (I) wherein A, D and Q are described herein.
    这种应用涉及可能作为PCSK9的抑制剂或以其他方式调节PCSK9活性的化合物,或其药用可接受的盐、溶剂化合物、前药或多型体,以及包含这些化合物的组合物和配方,以及使用和制备这些化合物的方法。化合物包括式(I)的化合物:(I)其中A、D和Q如本文所述。
  • [EN] TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES<br/>[FR] TRIAZOLES POUR LE TRAITEMENT DE MALADIES LIÉES À LA DÉMYÉLINISATION
    申请人:VERTEX PHARMA
    公开号:WO2016197009A1
    公开(公告)日:2016-12-08
    The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
    该发明涉及式I和I'的三唑化合物或其药学上可接受的盐,用作脱髓鞘疾病的调节剂:该发明还提供了包括该发明化合物的药学上可接受的组合物,以及在治疗各种脱髓鞘和神经退行性疾病,包括多发性硬化症中使用这些组合物的方法和工具包。
  • [EN] SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS<br/>[FR] INHIBITEURS À PYRIDINE SUBSTITUÉE DE LA TYROSINE KINASE DE LA RATE (SYK)
    申请人:MERCK SHARP & DOHME
    公开号:WO2013192098A1
    公开(公告)日:2013-12-27
    The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy,Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
    该发明提供了Formula (I)中的某些取代吡啶化合物或其药用可接受的盐,其中R1、R2、R3、R4、Rcy、Cy和t如本文所定义。该发明还提供了包括这些化合物的药物组合物,以及利用这些化合物治疗由脾酪氨酸激酶(Syk)介导的疾病或症状的方法。
  • [EN] PYRAZOLYL DERIVATIVES AS SYK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLYLE EN TANT QU'INHIBITEURS DE SYK
    申请人:MERCK SHARP & DOHME
    公开号:WO2013192125A1
    公开(公告)日:2013-12-27
    The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    本发明提供了一种新型的嘧啶酮衍生物,其化学式为I,它们是脾酪氨酸激酶的有效抑制剂,并且在治疗和预防由该酶介导的疾病方面具有用处,如哮喘、慢性阻塞性肺病、类风湿性关节炎和癌症。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐